FDA OKs new multiple sclerosis drug

WASHINGTON — The Food and Drug Administration said Wednesday it approved a new drug from Biogen Idec to control multiple sclerosis in adults with hard-to-treat forms of the disease.

The twice-a-day capsules, called Tecfidera, offer a new option for multiple sclerosis, a debilitating disease in which the body attacks its own nervous system. Cambridge, Mass.-based Biogen Idec already sells two other drugs for the disease, but both require injections.

There is no cure for multiple sclerosis and most patients experience relapses of symptoms, including loss of balance, weakness in arms and legs, and blurred vision. Over time patients usually become weaker and less coordinated. More than 2 million people worldwide have the disease, with about 400,000 of them in the U.S., according to Biogen.

The FDA said it approved Tecfidera based on two studies showing patients taking the drug had fewer relapses than patients taking a dummy pill.

The approval gives Biogen a new product in an increasingly crowded field of multiple sclerosis drugs.

The biotech drugmaker already sells the once-a-week multiple sclerosis injection Avonex. It also markets the once-a-month injection Tysabri through a partnership with Elan Corp. PLC of Ireland. However, Tysabri’s severe side effects have curtailed its use.

Tecfidera is designed to be taken orally, which could make it a preferred option for patients and doctors.

A Biogen executive said Wednesday that its three drugs would be used to treat different groups of patients.

“Multiple sclerosis is a reasonably complex disease and we think there are a lot of needs out there,” said Tony Kingsely, a vice president at Biogen. “By having three drugs out there I think we can address a lot of those needs.”

Kinglsey said the company will announce the pricing of the drug when it begins shipping in the next week.

Novartis launched the first pill-based multiple sclerosis drug, Gilenya, in March 2011. Sanofi won FDA approval for a second pill, its drug Aubagio, last September.

The top-selling drug for the disease worldwide is Copaxone, which is made by Teva Pharmaceutical Industries. That injection had sales of nearly $4 billion last year, according to Teva’s latest financial report.

Avonex and Tysabri had annual sales of $2.7 billion and $1.5 billion in 2011, the most recent year for which Biogen has reported annual sales.

Biogen Idec Inc. shares rose $5.59, or 3.2 percent, to close Wednesday at $182.68.

More in Local News

Inslee’s budget solves school funding with help from carbon

His budget would use reserves to boost education, then replenish them with a carbon tax or fee.

Man, 29, injured by shots fired at Everett thrift store

The gunfire followed an argument in the parking lot of Value Village on Evergreen Way.

Police: He made an appointment, then tried to rob the bank

A lawyer is accused of donning a fake beard and telling a teller that a gunman was outside.

Lynnwood robbery leads to lockdown at Edmonds schools

Edmonds police said it was just a precaution as they search around Edmonds-Woodway High School.

Marysville 7-Eleven hit by armed robbers

Officers set up a perimeter and brought in a police dog, but the man couldn’t be found.

In adult court, four teens plead not guilty to murder

Prosecutors allege they worked together to plan and execute a drug robbery in Everett.

2 women struck, injured while crossing busy roads

The first happened Wednesday night in Everett. The second was Thursday morning in Edmonds.

Drive-by shooting reported in Marysville neighborhood

Police said there was no evidence to indicate it was targeted at a specific person or property.

Trooper’s car struck when he was arresting man for DUI

She drove away but was arrested for investigation of driving while the influence and hit-and-run.

Most Read